BEAM-BD Trial: Antidepressants in Bipolar 1 Depression

The BEAM-BD trial, as presented in the New England Journal of Medicine in 2023, was a multisite, double-blind, randomized, placebo-controlled trial with the objective of comparing the maintenance of treatment with adjunctive escitalopram or bupropion XL versus discontinuation of antidepressant … Read More